Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
R647182-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$500.90
|
|
|
R647182-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$850.90
|
|
|
R647182-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,800.90
|
|
|
R647182-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$3,000.90
|
|
|
R647182-100mg
|
100mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$4,600.90
|
|
| Synonyms | 5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-thiazolidinedione | SCHEMBL1814433 | HY-16433 | CAS-79714-31-1 | Q27088451 | Risarestat | MS-24804 | 5-(3-Ethoxy-4-(pentyloxy)phenyl)-2,4-thiazolidinedione | 5-(3-ethoxy-4-pentoxyphenyl)-1,3-thiazolidine-2,4-dione | CS |
|---|---|
| Specifications & Purity | ≥98% |
| Biochemical and Physiological Mechanisms | Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. In Vivo Risarestat inhibits the accumulation of dulcitol in a dose-dependent manner, except for the 1.0% solution which has an activity comparable to the 0.25% solution . Risarestat peaks in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminishes time-dependently over a period of 24 hours. Risarestat remains detectable in the lens up to 24 hours, with a peak concentration at 2 hours after instillation. The anterior surface area of superficial cells in the group treated with Risarestat is significantly decreases from a mean value of 881 to 728 microns 2 . Corneal sensitivity significantly improves from 5.36 to 1.37 g/mm 2. Animals treated with Risarestat shows a significant increase in the mean blinkresponse compared to untreated galactose-fed rats and does not differ significantly from controls towards the completion of the 7 month study. Animals treated topically with Risarestat and untreated galactose-fed rats develop bilateral nuclear cataracts within 3 weeks. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Benzenoids |
| Class | Phenol ethers |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Phenol ethers |
| Alternative Parents | Phenoxy compounds Thiazolidinediones Alkyl aryl ethers Dicarboximides Thiocarbamic acid derivatives Organic carbonic acids and derivatives Azacyclic compounds Organopnictogen compounds Organonitrogen compounds Organic oxides Hydrocarbon derivatives Carbonyl compounds |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Phenoxy compound - Phenol ether - Alkyl aryl ether - Thiazolidinedione - Monocyclic benzene moiety - Dicarboximide - Thiazolidine - Thiocarbamic acid derivative - Carbonic acid derivative - Organoheterocyclic compound - Ether - Carboxylic acid derivative - Azacycle - Organic oxide - Organopnictogen compound - Organooxygen compound - Organonitrogen compound - Organic nitrogen compound - Carbonyl group - Organic oxygen compound - Hydrocarbon derivative - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. |
| External Descriptors | Not available |
|
|
|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | 5-(3-ethoxy-4-pentoxyphenyl)-1,3-thiazolidine-2,4-dione |
|---|---|
| INCHI | InChI=1S/C16H21NO4S/c1-3-5-6-9-21-12-8-7-11(10-13(12)20-4-2)14-15(18)17-16(19)22-14/h7-8,10,14H,3-6,9H2,1-2H3,(H,17,18,19) |
| InChIKey | CRPGRUONUFDYBG-UHFFFAOYSA-N |
| Smiles | CCCCCOC1=C(C=C(C=C1)C2C(=O)NC(=O)S2)OCC |
| Isomeric SMILES | CCCCCOC1=C(C=C(C=C1)C2C(=O)NC(=O)S2)OCC |
| Alternate CAS | 79714-31-1 |
| PubChem CID | 133264 |
| MeSH Entry Terms | 5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione;CT 112;CT-112;risarestat |
| Molecular Weight | 323.41 |
| Solubility | DMSO : 105 mg/mL (324.67 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 323.400 g/mol |
| XLogP3 | 3.900 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | 323.119 Da |
| Monoisotopic Mass | 323.119 Da |
| Topological Polar Surface Area | 89.900 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 390.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |